FDA Eases Clozapine Rules For Children
2026-09-04
Regulatory caution may be hurting the very children it aims to protect. A recent Food and Drug Administration move stripped away some of the tightest controls on clozapine, the second‑generation antipsychotic long known as the drug of last resort for treatment‑resistant schizophrenia. Gone are some of the most rigid blood‑test mandates that turned every prescription into a bureaucratic obstacle course for families and clinicians.
The paradox is stark. Clozapine is, by most comparative trials and meta‑analyses, the only antipsychotic with robust evidence for reducing suicidal behavior and violent psychosis in patients who fail standard dopamine D2 receptor blockers, yet it remains sidelined. Psychiatrist Nitin Gogtay calls it “one of the most underused drugs in all of medicine,” a line that captures how fear of agranulocytosis, a rare but serious suppression of white blood cell counts, has overshadowed its superior efficacy in refractory cases.
The deeper problem is not chemistry but culture. Electronic registries, absolute neutrophil count monitoring and risk evaluation and mitigation strategies created a safety net, yet they also built a psychological moat around clozapine that many pediatric psychiatrists hesitate to cross. Even with the Food and Drug Administration relaxing parts of that closed‑loop system, medical training, malpractice anxiety and underfunded community services still nudge prescribers toward blander, less effective options, leaving some of the sickest children trapped in avoidable disability.
Loading...
